naltrexone targets OPRK1

Evidence from: primary | all sources

Evidence (2 sources)

Naltrexone is a non-selective antagonist of mu, kappa, and delta opioid receptors

confidence: 0.98

activity at delta and kappa opioid receptors, in addition to mu, may underlie the effects of naltrexone on alcohol-related phenotypes

confidence: 0.85